Core Insights - Processa Pharmaceuticals, Inc. is actively participating in multiple investor and industry conferences in September 2024, including the H.C. Wainwright 26th Annual Global Investment Conference and the European Society for Medical Oncology (ESMO) Congress 2024 [1][2] Group 1: Conference Participation - Management will hold one-on-one meetings with investors and deliver a company presentation at the H.C. Wainwright conference from September 9-11, 2024 [1] - A recorded presentation will be available on demand starting September 9th at 7:00 am Eastern time on the company's website [1] - At the ESMO Congress from September 13-17, 2024, management will engage with clinicians, researchers, industry key opinion leaders, and potential partners [1] Group 2: Company Overview - Processa is a clinical-stage pharmaceutical company focused on developing Next Generation Chemotherapy (NGC) drugs that offer improved safety and efficacy [2] - The NGC drugs are modifications of existing FDA-approved oncology therapies, altering their metabolism and/or distribution while preserving their cancer-killing mechanisms [2] - The company's strategy combines a novel oncology pipeline with proven active molecules and a Regulatory Science Approach to create more effective therapy options with better tolerability for cancer patients [2]
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September